Clinical trials · New York
Leukemia clinical trials in New York
We’re tracking 183 recruiting leukemia studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Commack, New YorkAges 18 years+ - NCT04679012RecruitingPhase 2
Polatuzumab plus chemotherapy for Richter’s transformation
This trial studies whether polatuzumab added to chemotherapy can improve outcomes in people whose CLL/SLL has transformed into a type of aggressive lymphoma called DLBCL. It may help shrink tumors and control the disease after this transformation.
New York, New YorkAges 18 years+ - NCT04806295Recruiting
National registry for people with blood cancers
This is a national research registry that collects information from people with blood cancer before, during, and after treatment. It may help researchers better understand care and outcomes and may connect you to future studies.
Rye Brook, New YorkAges 21 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
New York, New YorkAges 18 years+ - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Vallhala, New YorkAges Up to 39 years - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
New York, New YorkAges 18 years+ - NCT05082519RecruitingPhase 2
Calorie reduction and activity to help chemo work in B-ALL
This Phase 2 study tests whether eating fewer calories and doing activity safely can make chemotherapy work better for children and young adults with newly diagnosed B-ALL. It aims to reduce chemo resistance, meaning help leukemia respond more strongly to treatment.
Los Angeles, CaliforniaAges 10–25 - NCT05108298Recruiting
Study to improve cancer survey reporting for young adults
This study focuses on collecting better self-reported information (from questionnaires) from young adults with cancer. It may help improve how future cancer trials understand symptoms and quality-of-life needs.
The Bronx, New YorkAges 18–39 - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Ithaca, New YorkAges 18 years+ - NCT05342584RecruitingPhase 1
Venetoclax plus intensive chemo for AML and advanced MDS
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
The Bronx, New YorkAges 18–75 - NCT05375617Recruiting
Study for newly diagnosed childhood cancers in Europe
This study follows children and teens with newly diagnosed certain leukemia (ALL) and certain favorable brain tumors to learn best care and outcomes. It may help your team compare standard treatments and monitor health over time.
New York, New YorkAges 3–21 - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Buffalo, New YorkAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Westbury, New YorkAges 18 years+ - NCT05643235Recruiting
Loop monitor to watch heart rhythms when starting a BTK inhibitor
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
New Hyde Park, New YorkAges 18 years+ - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
The Bronx, New YorkAges Up to 26 years - NCT05875805Recruiting
Telehealth planning for future care decisions
This trial tests a telehealth (video or phone) program that helps people with certain blood cancers plan their future care preferences. It may help you and your chosen support person communicate your wishes clearly, especially if you become too sick to speak for yourself.
Rochester, New YorkAges 60 years+ - NCT05963971Recruiting
Bilingual online program to prevent weight gain in childhood leukemia
This trial tests a bilingual, online program to help children and teens who have ALL (a type of leukemia) stay at a healthy weight during the maintenance phase of treatment. It may help lower the chance of gaining too much weight while on chemotherapy.
New York, New YorkAges 5–21 - NCT05986240RecruitingPhase 1
Danvatirsen with or without venetoclax for advanced MDS or AML
This trial tests a new drug called danvatirsen, first alone and then combined with venetoclax, for people with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if this approach can help when other options have stopped working.
The Bronx, New YorkAges 18 years+ - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Stony Brook, New YorkAges 18 years+ - NCT06074666Recruiting
Parent training to boost medication adherence in pediatric leukemia
This study tests a new parenting program to help improve how well children with leukemia take their oral medications at home. The program focuses on building helpful skills for giving daily medicine.
Buffalo, New YorkAges 3–9 - NCT06137118RecruitingPhase 1/Phase 2
AZD0486 for B-cell acute lymphoblastic leukemia
This trial tests a new drug called AZD0486 for people with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It aims to see if the drug can help control the cancer.
New York, New YorkAges 12 years+ - NCT06159491RecruitingPhase 1/Phase 2
Pacritinib for chronic myelomonocytic leukemia (CMML)
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
New York, New YorkAges 18 years+ - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
New York, New YorkAges 12 years+ - NCT05442216RecruitingPhase 2
Study of tagraxofusp, azacitidine, and venetoclax for secondary AML
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
Buffalo, New YorkAges 18 years+
Leukemia trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting leukemia studies listed above.
- Columbia University Irving Medical Center · 4 studies
- Memorial Sloan Kettering Cancer Center · 4 studies
- Montefiore Medical Center · 4 studies
- Children's Hospital at Montefiore · 2 studies
- Roswell Park Comprehensive Cancer Center · 2 studies
- Weill Cornell Medicine · 2 studies
- Ascentage Investigative Site #1151
- Ascentage Investigative Site #1160
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in New York?
- Yes. We're currently tracking 183 recruiting leukemia studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.